COMMUNIQUÉS West-GlobeNewswire

Ocular Therapeutix™ to Participate in March Investor Conferences
24/02/2026
BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the [...]
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
24/02/2026
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
24/02/2026
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the [...]
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
24/02/2026
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
24/02/2026
WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
ASTRA Therapeutics appoints Industry Leader Fabian Kausche as Chairman of the Board of Directors
24/02/2026
Villigen, Switzerland, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dr. Fabian Kausche, a distinguished animal health executive, joins ASTRA Therapeutics to strengthen strategic leadership and long-term value creation. Appointment [...]
Amber Therapeutics strengthens its Board and Leadership team, opens UK headquarters and expands EU feasibility study for mixed urinary incontinence, increasing momentum towards a pivotal trial in the US
24/02/2026
Oxford, UK – 24 February 2026 – Amber Therapeutics today announced a series of updates to its business highlighting the significant progress it has made since closing its $100 million (£80 million) Series A financing in [...]
Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China
24/02/2026
UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk In a placebo-controlled phase 2 trial in Chinese people with [...]
Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis
24/02/2026
Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu ® Clinical trial with AVA6103 is expected to be initiated in Q1 2026 LONDON [...]
Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting
24/02/2026
Press Release Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting February 24, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox [...]
Nicox présente des données de Phase 3 positives confirmant le profil thérapeutique de NCX 470 lors du congrès annuel 2026 de l’American Glaucoma Society (AGS)
24/02/2026
Communiqué de presse Nicox présente des données de Phase 3 positives confirmant le profil thérapeutique de NCX 470 lors du congrès annuel 2026 de l’ American Glaucoma Society (AGS) 24 février 2026 – publication à 7H30 [...]
Boston Vitality Declares To Continue Leading In Men's Hormone Health Care
24/02/2026
STONEHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Boston Vitality, a medical practice located in Stoneham, Massachusetts, remains committed to further clinical focus on hormone health, diagnostic assessment, and [...]
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
23/02/2026
EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative [...]
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
23/02/2026
FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a [...]
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
23/02/2026
Highl ights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind 1 of $8.1 million. Full year 2025 [...]
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
23/02/2026
Reported rinzimetostat (formerly ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with [...]
Mangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
23/02/2026
Dallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform [...]
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
23/02/2026
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance
23/02/2026
Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025 Generates free cash flow in the Fourth Quarter 2025 SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: [...]

Pages